Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease

Tomas Jernberg; Christopher D. Payne; Kenneth J. Winters; Christelle Darstein; John T. Brandt; Joseph A. Jakubowski; Hideo Naganuma; Agneta Siegbahn; Lars Wallentin

doi:10.1093/eurheartj/ehi877

Abstract

In this population, prasugrel (40-60 mg LD and 10-15 mg MD) achieves greater IPA and a lower proportion of pharmacodynamic non-responders compared with the approved clopidogrel dosing.

Keywords

PrasugrelClopidogrelMedicineAspirinPharmacodynamicsCoronary artery diseaseInternal medicineDosingLoading doseMaintenance dosePlateletPharmacologyCardiologyAnesthesiaPharmacokinetics

Affiliated Institutions

Related Publications

Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease

Lars Wallentin , Christoph Varenhorst , Stefan James +6 more

In aspirin-treated subjects with coronary artery disease, prasugrel 60/10 mg provides faster onset and greater inhibition of P2Y(12) receptor-mediated platelet aggregation than ...

2007 European Heart Journal 455 citations

Dose Effect of Clopidogrel Reloading in Patients Already on 75-mg Maintenance Dose

Jean‐Philippe Collet , Johanne Silvain , Antoine Landivier +8 more

Background— Clopidogrel loading has mostly been studied in clopidogrel-naïve patients. Whether clopidogrel-treated patients readmitted for an acute coronary syndrome or percuta...

2008 Circulation 87 citations

Pharmacology of CS-747 (prasugrel, LY640315), a Novel, Potent Antiplatelet Agent with in Vivo P2Y<sub>12</sub>Receptor Antagonist Activity

Y. Niitsu , Joseph A. Jakubowski , Atsuhiro Sugidachi +1 more

CS-747 (prasugrel, LY640315) is a member of the thienopyridine class of oral platelet aggregation inhibitors that includes ticlopidine and clopidogrel. A single oral administrat...

2005 Seminars in Thrombosis and Hemostasis 233 citations

Randomized Comparison of Prasugrel (CS-747, LY640315), a Novel Thienopyridine P2Y <sub>12</sub> Antagonist, With Clopidogrel in Percutaneous Coronary Intervention

Stephen D. Wiviott , Elliott M. Antman , Kenneth J. Winters +8 more

Background— Despite the current standard antiplatelet regimen of aspirin and clopidogrel (with or without glycoprotein IIb/IIIa inhibitors) in percutaneous coronary intervention...

2005 Circulation 378 citations

Increased Mortality With Oral Platelet Glycoprotein IIb/IIIa Antagonists

Derek P. Chew , Deepak L. Bhatt , Shelly Sapp +1 more

Background —Numerous clinical trials have established the benefits of intravenous glycoprotein IIb/IIIa inhibition in the management of coronary artery disease. In contrast, the...

2001 Circulation 358 citations

Publication Info

Year: 2006
Type: article
Volume: 27
Issue: 10
Pages: 1166-1173
Citations: 535
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

535

OpenAlex

Cite This

APA Style

                            
                                
                                    Tomas Jernberg, 
                                
                                    Christopher D. Payne, 
                                
                                    Kenneth J. Winters
                                
                                et al.
                            
                            (2006). 
                            Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. 
                            European Heart Journal
                            , 27
                            (10)
                            , 1166-1173.
                            https://doi.org/10.1093/eurheartj/ehi877
                        

Identifiers

DOI: 10.1093/eurheartj/ehi877